Blue Earth Diagnostics announced that their scan, Axumin (fluciclovine F 18) injection has been added to the National Comprehensive Cancer Network® (“NCCN”) Clinical Practice Guidelines in Oncology for Prostate Cancer. These updated NCCN Guidelines state that F‐18 fluciclovine PET/CT or PET/MRI should be considered in the clinical workup of patients with recurrence or progression of their prostate cancer.
This recommendation is based on uniform NCCN consensus that the intervention is appropriate.
The addition to the NCCN Guidelines, along with the FDA approval two years ago should make obtaining insurance company coverage easier. If you are not approved for the scan you should file an appeal and make it clear that Axumin is both FDA approved and is now a part of the NCCN Guidelines.
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.
